Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This phase 2 trial is testing the drug cemiplimab as a first treatment for people with advanced basal cell carcinoma, a type of skin cancer. The study will enroll 34 adults who have not received prior treatment with hedgehog inhibitors. Researchers want to see if cemiplimab can s…

This phase 2 trial is testing whether combining radiofrequency ablation (a heat treatment) with chemotherapy and the immunotherapy drug durvalumab can improve survival in people with advanced bile duct cancer that cannot be removed by surgery. The study will enroll 42 participant…

This phase 2 trial is testing a combination of two drugs—futibatinib (a targeted therapy) and tislelizumab (an immunotherapy)—in people with colorectal cancer and other solid tumors that have spread. The study aims to see if the combo can shrink tumors and how safe it is. About 3…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) to a radiation bead treatment (Y-90 SIRT) can shrink liver tumors that cannot be removed by surgery. About 55 adults with intermediate-stage liver cancer will receive the combination. The main g…

This study tests whether combining two drugs—fruquintinib and tislelizumab—can help people with a specific type of advanced colorectal cancer (MSS/pMMR) that has not spread to the liver. About 140 adults will receive the combination to see if it slows cancer growth. The goal is t…

This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It will test if adding a procedure called TIPS (which places a small tube in the liver to improve blood flow) can help keep the liver working better for…

This study tests a new combination of three drugs (zanidatamab, pembrolizumab, and chemotherapy) in people with advanced stomach or esophageal cancer that has spread. Participants must have tumors with specific markers (HER2 and PD-L1) and have not received prior treatment for me…

This study tests a combination of two drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced or metastatic penile cancer that cannot be cured by surgery. The goal is to see if the drugs shrink tumors and help patients live longer. About 25 men will tak…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…

This registry is collecting information from up to 9,000 people in Germany with sarcoma or carcinosarcoma. Researchers will track how often different subtypes occur, how they progress, and what treatments patients receive. The goal is to better understand these rare cancers and i…

This study is watching how lung cancer patients do when they get the drug tislelizumab in normal doctor visits, not in a strict research setting. About 240 people with small cell or non-small cell lung cancer will take part. The goal is to see how long they live, how the drug aff…